SERPINA1 and pulmonary emphysema: In the past 25 years, it has not been possible to demonstrate in randomised, placebo-controlled trials of intravenous alpha-1-antitrypsin treatment a clinical meaningful important difference on FEV1 decline in AATD patients with pulmonary emphysema [88].